Skip to main content

Table 5 Phase 1 and early phase 1 small molecule inhibitors/modulators for RRMM, as of December 31, 2020, with study start date after January 1, 2019

From: Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Target pathway Product name (NCT) Study sponsor Estimated enrollment Country
Adenosine-2A receptor Ciforadenant (CPI-444) (NCT04280328) Corvus 28 United States
Arginase INCB001158 (NCT03837509) Incyte 98 United States, Germany, Spain
Bcl-2/Bcl-xL (apoptosis regulator) AZD0466 (NCT04214093) AstraZeneca 102 United States
Bcl-2 S65487 (NCT03755154) Institut de Recherches Internationales Servier 60 Australia, France, Spain, United Kingdom
BTK (Bruton’s tyrosine kinase) Ibrutinib (NCT03702725) Alliance Foundation 28 United States
Cereblon E3 ubiquitin ligase (CELMoD – protein homeostasis) CC-92480 (NCT03989414) Celgene 215 (includes NDMM) United States, Canada, Denmark, Finland, Spain, United Kingdom
IL-15 receptor (cytokine signaling) NKTR-255 (NCT04136756) Nektar 87 United States
IRF4 (lymphocyte transcriptional factor) ION251 (NCT04398485) Ionis 80 United States
JAK (Janus kinase/tyrosine kinase) Ruxolitinib (NCT03773107) Incyte 48 United States
LMP7 (proteasome complex subunit) M3258 (NCT04075721) EMD Serono 48 United States, France
Mcl-1 (apoptosis control) ABBV-467 (NCT04178902) AbbVie 54 United States, Australia, France, Israel, Japan, Spain, Taiwan
Mcl-1 PRT1419 (NCT04543305) Prelude 36 United States
NEDD8 (ubiquitin-like protein) Pevonedistat (NCT03770260) National Cancer Institute 66 United States
p300/CBP (transcriptional coactivating proteins) CCS1477 (NCT04068597) CellCentric 90 United Kingdom
Proteasome inhibitor TQB3602 (NCT04275583) Chia Tai Tianqing 40 China
RAD51 (DNA repair protein) CYT-0851 (NCT03997968) Cyteir 165 United States
S100A9 (regulation of immune response and inflammation) Tasquinimod (NCT04405167) University of Pennsylvania 54 United States
TIGIT (T and NK cell immune receptor) COM902 (NCT04354246) Compugen 45 United States
TIGIT Tiragolumab (NCT04045028) Genentech 52 United States, Korea
Anti-TIGIT and anti-LAG BMS-986016 and BMS-986207 (NCT04150965) Multiple Myeloma Research Consortium 104 United States
TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) Eftozanermin alfa (ABBV-621) (NCT04570631) AbbVie 40 United States, France, German, Italy, Japan, Spain
Specific targeted therapy based on mutations uncovered with genomic studies MyDRUG (NCT03732703) Multiple Myeloma Research Consortium 228 United States
Specific targeted therapy based on mutations uncovered with genomic studies SMMART PRIME (NCT03878524) Oregon Health and Science University 40 United States